| scholarly article | Q13442814 |
| P50 | author | Manfred Wuhrer | Q45905459 |
| Jeanette H Leusen | Q57039110 | ||
| Frank E J Coenjaerts | Q88096441 | ||
| P2093 | author name string | C Erik Hack | |
| Jan Meeldijk | |||
| Karli R Reiding | |||
| Louis J Bont | |||
| J H Marco Jansen | |||
| Maaike Nederend | |||
| Shamir R Jacobino | |||
| Daan Augustijn | |||
| J Frederiek Reijneveld | |||
| P2860 | cites work | Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus | Q45747360 |
| Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus | Q45759631 | ||
| Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. | Q46508058 | ||
| An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. | Q51618532 | ||
| Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. | Q51784332 | ||
| Episodes of natural selection shaped the interactions of IgA-Fc with FcalphaRI and bacterial decoy proteins. | Q52840312 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans | Q80801103 | ||
| Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides | Q83511731 | ||
| Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo | Q24568302 | ||
| Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity | Q26823301 | ||
| MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality Control Developed for Glycomic and Glycoproteomic MALDI-MS. | Q31023082 | ||
| Risk of primary infection and reinfection with respiratory syncytial virus | Q34188122 | ||
| The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions | Q34453640 | ||
| Fc receptor inside-out signaling and possible impact on antibody therapy. | Q34499280 | ||
| In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells | Q35064867 | ||
| High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification | Q35169163 | ||
| Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus | Q35618515 | ||
| Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. | Q36127055 | ||
| Production of secretory immunoglobulin A by a single mammalian cell | Q36184551 | ||
| Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV | Q36214139 | ||
| Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. | Q36487349 | ||
| A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. | Q37138274 | ||
| Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting | Q37138332 | ||
| Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography | Q37381649 | ||
| The role of secretory antibodies in infection immunity | Q37778734 | ||
| Structure and function relationships in IgA. | Q37936765 | ||
| Neutrophils in respiratory syncytial virus infection: A target for asthma prevention | Q38567537 | ||
| Mouse and human FcR effector functions | Q38615349 | ||
| IgA as therapeutic antibody | Q38644411 | ||
| Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing | Q38832457 | ||
| IgA EGFR antibodies mediate tumour killing in vivo | Q39114924 | ||
| Crosstalk between human IgG isotypes and murine effector cells | Q39283830 | ||
| Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. | Q39593092 | ||
| Serum-free production and purification of chimeric IgA antibodies | Q39854415 | ||
| Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities | Q40077073 | ||
| Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract | Q40158643 | ||
| Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection | Q40603204 | ||
| P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice | Q41166170 | ||
| Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. | Q41877699 | ||
| Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection | Q42411056 | ||
| The inhibitory effect of C-reactive protein on bacterial phosphorylcholine platelet-activating factor receptor-mediated adherence is blocked by surfactant | Q44074395 | ||
| Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial | Q45458064 | ||
| Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease | Q45710733 | ||
| Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies | Q45722681 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 453-462 | |
| P577 | publication date | 2018-03-19 | |
| P1433 | published in | Monoclonal Antibodies | Q6714645 |
| P1476 | title | Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo | |
| P478 | volume | 10 |
| Q92021897 | Antibody development for preventing the human respiratory syncytial virus pathology |
| Q59354557 | Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. |
| Q64060972 | Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease |
| Q98386109 | The role of IgG Fc receptors in antibody-dependent enhancement |
Search more.